Wisconsin Alumni Research Foundation
A Leader in University Technology Transfer since 1925
Home | Printer Friendly
Technologies
New Inventions
New Patents
Agriculture (144)
Analytical Instrumentation (129)
Cleantech (89)
Diagnostic Assays (61)
Drug Discovery (164)
Education & Training (9)
Engineering (12)
Engines & Power Electronics (54)
Food & Supplements (56)
Information Technology (120)
Materials & Chemicals (94)
Medical Devices (76)
Medical Imaging (125)
Micro & Nanotech (69)
Miscellaneous (2)
Pharmaceuticals & Vitamin D (209)
Plasma Processing (25)
Pluripotent Cells (23)
Culture
Differentiation
Fundamental technologies
Related technologies
Tools
Radiation Therapy (38)
Research Tools (287)
Semiconductors & Integrated Circuits (55)
Veterinary (20)
WARF: P04434US Pluripotent Cells
Method of Forming Dendritic Cells from Embryonic Stem Cells
INVENTORS Igor Slukvin, James Thomson, Maksym Vodyanyk, Maryna Gumenyuk
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method for inducing human embryonic stem cells to differentiate into dendritic cells.
OVERVIEW
Dendritic cells are used as a base for vaccines and in the study of antigen processing within the human body. However, obtaining large quantities of the cells, which are generated in bone marrow, is labor-intensive and risky for the donor.
THE INVENTION
UW-Madison researchers have developed an in vitro method for inducing human embryonic stem cells to differentiate into dendritic cells. Stem cells are cultured successively in three different environments for between seven and 10 days each. The first environment induces them to become hematopoietic cells, the second directs the hematopoietic cells to become myeloid precursor cells, and the third causes the myeloid precursor cells to develop into immature dendritic cells. The resulting dendritic cells are morphologically, phenotypically and functionally similar to dendritic cells in vivo.
APPLICATIONS
  • Production of large amounts of dendritic cells
  • Cells can potentially be used in gene therapy to treat cancer or graft rejection.
KEY BENEFITS
  • Provides an in vitro method of obtaining large amounts of fully functional dendritic cells and myeloid dendritic cell precursors
  • High yielding - greater than 95 percent of cultured stem cells differentiate into dendritic cells
  • High production allows multiple vaccinations to be given from one line of cells.
  • Low risk of pathogen contamination
  • Efficient; only requires exposing stem cells to differentiation-mediating factors, rather than extracting dendritic cells from the blood
STAGE OF DEVELOPMENT
Successfully used to differentiate multiple human embryonic stem cell lines into dendritic cells.
ADDITIONAL INFORMATION
For More Information About the Inventors
Tech Fields
Pluripotent Cells - Differentiation
Drug Discovery - Stem cells
CONTACT INFORMATION
For current licensing status, please contact our team at licensing@warf.org or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF Medal of Technology Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.


Contact Us | WARF Extranet | Privacy Policy | IMS Powered